Observations placeholder
Halaven
Identifier
019099
Type of Spiritual Experience
Number of hallucinations: 2
Background
A description of the experience
Eribulin is an anticancer drug under the trade name Halaven. The mesylate salt was approved by the U.S. Food and Drug Administration on November 15, 2010, to treat patients with metastatic breast cancer who have received at least two prior chemotherapy regimens for late-stage disease, including both anthracycline- and taxane-based chemotherapies. It was approved by Health Canada on December 14, 2011, for treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease
Eribulin is also being investigated. for use in a variety of other solid tumors, including non-small cell lung cancer, prostate cancer and sarcoma.
On Dec, 21, 2015: 458 people reported to have side effects when taking Halaven. Among them, 2 people (0.44%) have Hallucination.
On Dec, 9, 2015: 458 people reported to have side effects when taking Halaven. Among them, 6 people (1.31%) have Death.
Time on Halaven when people have Death :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Death | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |